ATE200733T1 - Pharmazeutische zubereitungen, die fluoxetin enthalten - Google Patents

Pharmazeutische zubereitungen, die fluoxetin enthalten

Info

Publication number
ATE200733T1
ATE200733T1 AT95304975T AT95304975T ATE200733T1 AT E200733 T1 ATE200733 T1 AT E200733T1 AT 95304975 T AT95304975 T AT 95304975T AT 95304975 T AT95304975 T AT 95304975T AT E200733 T1 ATE200733 T1 AT E200733T1
Authority
AT
Austria
Prior art keywords
pharmaceutical preparations
preparations containing
fluoxetine
containing fluoxetine
dispersible tablets
Prior art date
Application number
AT95304975T
Other languages
English (en)
Inventor
Mendizabal Flavia Arce
Original Assignee
Lilly Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8286976&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE200733(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lilly Sa filed Critical Lilly Sa
Application granted granted Critical
Publication of ATE200733T1 publication Critical patent/ATE200733T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Inorganic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT95304975T 1994-07-20 1995-07-17 Pharmazeutische zubereitungen, die fluoxetin enthalten ATE200733T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ES09401593A ES2082723B1 (es) 1994-07-20 1994-07-20 Formulacion farmaceutica de fluoxetina en forma dispersable.

Publications (1)

Publication Number Publication Date
ATE200733T1 true ATE200733T1 (de) 2001-05-15

Family

ID=8286976

Family Applications (1)

Application Number Title Priority Date Filing Date
AT95304975T ATE200733T1 (de) 1994-07-20 1995-07-17 Pharmazeutische zubereitungen, die fluoxetin enthalten

Country Status (30)

Country Link
US (1) US5747068A (de)
EP (3) EP1070501A1 (de)
JP (1) JPH0840884A (de)
KR (1) KR100360130B1 (de)
CN (2) CN1440745B (de)
AT (1) ATE200733T1 (de)
AU (2) AU692550B2 (de)
BR (1) BR9503386A (de)
CO (1) CO4410195A1 (de)
CY (1) CY2241B1 (de)
CZ (1) CZ287378B6 (de)
DE (2) DE693281T1 (de)
DK (1) DK0693281T3 (de)
ES (2) ES2082723B1 (de)
FI (3) FI20011852L (de)
GR (2) GR960300064T1 (de)
HU (1) HU228859B1 (de)
IL (1) IL114641A (de)
MY (1) MY114776A (de)
NO (1) NO312225B1 (de)
NZ (1) NZ272610A (de)
PE (1) PE33996A1 (de)
PL (1) PL181359B1 (de)
PT (1) PT693281E (de)
RU (1) RU2145850C1 (de)
SI (1) SI0693281T1 (de)
TR (1) TR199500878A2 (de)
TW (1) TW404840B (de)
UA (1) UA41346C2 (de)
ZA (1) ZA956074B (de)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE206304T1 (de) * 1995-12-27 2001-10-15 Janssen Pharmaceutica Nv Bioadhesive feste arzneimittelform
PT1166651E (pt) * 1996-02-29 2005-04-29 Fujisawa Pharmaceutical Co Granulos de desintegracao rapida de um edulcorante sintetico contendo acido silicico e/ou dioxido de silicio
US8071128B2 (en) 1996-06-14 2011-12-06 Kyowa Hakko Kirin Co., Ltd. Intrabuccally rapidly disintegrating tablet and a production method of the tablets
US5910319A (en) 1997-05-29 1999-06-08 Eli Lilly And Company Fluoxetine enteric pellets and methods for their preparation and use
US5904937A (en) * 1997-10-03 1999-05-18 Fmc Corporation Taste masked pharmaceutical compositions
NZ503820A (en) * 1997-10-09 2004-02-27 Dexcel Pharma Technologies Ltd A delayed followed by immediate release drug delivery system containing a core and a coating
JP4504467B2 (ja) * 1998-07-30 2010-07-14 佐藤製薬株式会社 口腔内崩壊性錠剤
US6399101B1 (en) 2000-03-30 2002-06-04 Mova Pharmaceutical Corp. Stable thyroid hormone preparations and method of making same
RU2174391C1 (ru) * 2000-10-24 2001-10-10 Открытое акционерное общество "Химико-фармацевтический комбинат "Акрихин" Фармацевтическая композиция с антидепрессантной активностью
HUP0401391A3 (en) * 2001-05-01 2009-06-29 Pfizer Prod Inc Method for manufacturing a low dose pharmaceutical composition having uniform drug distribution and potency and the pharmaceutical compositin
CZ20033116A3 (cs) * 2001-05-15 2004-09-15 Warner-Lambert Company Llc Způsob výroby lékové formy fenytoinu sodného užívající kompaktor
US6509040B1 (en) 2001-06-22 2003-01-21 R.P. Scherer Corporation Fast dispersing dosage forms essentially free of mammalian gelatin
US9358214B2 (en) * 2001-10-04 2016-06-07 Adare Pharmaceuticals, Inc. Timed, sustained release systems for propranolol
US20030099699A1 (en) * 2001-11-13 2003-05-29 Hanshew Dwight D. Storage stable thyroxine active drug formulations and methods for their production
US6645526B2 (en) * 2001-11-13 2003-11-11 Mylan Pharmaceuticals, Inc. Storage stable thyroxine active drug formulations and methods for their production
US20030113366A1 (en) * 2001-12-14 2003-06-19 Macgregor Alexander Reverse-micellar delivery system for controlled transportation and enhanced absorption of agents
FR2834889B1 (fr) * 2002-01-18 2004-04-02 Roquette Freres Forme pharmaceutique solide orodispersible
GB2392385A (en) * 2002-09-02 2004-03-03 Cipla Ltd Pharmaceutical preparations comprising a 5HT uptake inhibitor and a homopolymer or copolymer of N-vinyl pyrrolidone
US8367111B2 (en) * 2002-12-31 2013-02-05 Aptalis Pharmatech, Inc. Extended release dosage forms of propranolol hydrochloride
US7390503B1 (en) 2003-08-22 2008-06-24 Barr Laboratories, Inc. Ondansetron orally disintegrating tablets
DE10351448A1 (de) * 2003-11-04 2005-06-09 Bayer Healthcare Ag Geschmackstoffhaltige Arzneimittelformulierungen mit verbesserten pharmazeutischen Eigenschaften
US8747895B2 (en) * 2004-09-13 2014-06-10 Aptalis Pharmatech, Inc. Orally disintegrating tablets of atomoxetine
US9884014B2 (en) 2004-10-12 2018-02-06 Adare Pharmaceuticals, Inc. Taste-masked pharmaceutical compositions
WO2006047493A2 (en) * 2004-10-21 2006-05-04 Eurand Pharmaceuticals Limited Taste-masked pharmaceutical compositions with gastrosoluble pore-formers
US20060105038A1 (en) * 2004-11-12 2006-05-18 Eurand Pharmaceuticals Limited Taste-masked pharmaceutical compositions prepared by coacervation
US9161918B2 (en) 2005-05-02 2015-10-20 Adare Pharmaceuticals, Inc. Timed, pulsatile release systems
CA2607098C (en) * 2005-05-17 2012-04-10 Actelion Pharmaceuticals Ltd Dispersible bosentan tablet
TWI383809B (zh) * 2005-06-29 2013-02-01 Otsuka Pharma Co Ltd 含有西洛他唑（ｃｉｌｏｓｔａｚｏｌ）之口腔崩解粉末
CN100353943C (zh) * 2005-07-04 2007-12-12 广州固志医药科技有限公司 乳酸氟罗沙星分散片及其制备方法
US20080020040A1 (en) * 2006-07-18 2008-01-24 Horizon Therapeutics, Inc. Unit dose form for administration of ibuprofen
WO2007012019A2 (en) * 2005-07-18 2007-01-25 Horizon Therapeutics, Inc. Medicaments containing famotidine and ibuprofen and administration of same
US8067451B2 (en) * 2006-07-18 2011-11-29 Horizon Pharma Usa, Inc. Methods and medicaments for administration of ibuprofen
FR2891147B1 (fr) * 2005-09-28 2007-12-07 Ethypharm Sa Comprimes orodispersibles de principes actifs amers
EP1993377B1 (de) 2006-03-03 2012-01-04 Symrise AG Konsumationsfähige pressagglomerate mit retardierter aromafreisetzung
US8067033B2 (en) * 2007-11-30 2011-11-29 Horizon Pharma Usa, Inc. Stable compositions of famotidine and ibuprofen
FR2910319B1 (fr) 2006-12-20 2011-06-03 Substipharm Dev Formulations pharmaceutiques dispersibles contenant de la fluoxetine
BRPI0811303A2 (pt) * 2007-05-08 2015-01-27 Hercules Inc Formulação de comprimido de desintegranção rápida robusta
CN102958515A (zh) 2009-12-02 2013-03-06 阿普塔利斯制药有限公司 非索非那定微胶囊及含有非索非那定微胶囊的组合物
AR079862A1 (es) * 2010-01-08 2012-02-22 Eurand Inc Composicion de topiramato con sabor enmascarado, un comprimido desintegrable oralmente que comprende la misma y metodo de preparacion
MX2011007675A (es) * 2011-07-19 2012-07-11 Cell Therapy And Technology S A De C V Procedimiento para la fabricacion de una composicion farmaceutica en forma de tabletas de liberacion prolongada conteniendo pirfenidona y su aplicacion en la regresion de la insuficiencia renal cronica, contractura capsular mamaria y fibrosis hepatica humanas.
KR101438629B1 (ko) 2013-02-04 2014-09-05 현대자동차 주식회사 체결 장치 및 그 제어 방법
HUE041983T2 (hu) 2013-12-27 2019-06-28 Chugai Pharmaceutical Co Ltd Tofogliflozint tartalmazó szilárd készítmények és eljárás ezek elõállítására
CN107106497A (zh) * 2014-10-03 2017-08-29 诺华股份有限公司 含alpelisib的药物组合物
CN107334742B (zh) * 2017-08-18 2020-01-31 山东力诺制药有限公司 一种盐酸氟西汀分散片及其制备方法
KR102453105B1 (ko) * 2020-10-26 2022-10-07 현대제철 주식회사 침지노즐 크리닝 장치
CN114699374B (zh) * 2022-04-01 2024-02-20 佛山市南海东方澳龙制药有限公司 一种猫犬专用盐酸氟西汀固体制剂及其制备和应用

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3034911A (en) * 1959-03-25 1962-05-15 Nat Starch Chem Corp Tablet disintegrants
US3091574A (en) * 1961-09-05 1963-05-28 Bristol Myers Co Tablet disintegrants
DE1228029C2 (de) * 1964-05-09 1973-05-17 Merck Ag E Verfahren zur Herstellung von Tabletten durch Pressen von Pulvergemischen ohne vorhergehende Granulation
NL159577B (nl) * 1968-02-15 1979-03-15 Organon Nv Werkwijze ter bereiding van snel desintegrerende vaste vormstukken.
US3622677A (en) * 1969-07-07 1971-11-23 Staley Mfg Co A E Compressed tablets containing compacted starch as binder-disintegrant ingredient
US3852421A (en) * 1970-03-23 1974-12-03 Shinetsu Chemical Co Excipient and shaped medicaments prepared therewith
US3725556A (en) * 1970-11-12 1973-04-03 D Hanssen Method of manufacturing rapidly disintegrating pharmaceutical tablets
US4194009A (en) * 1974-01-10 1980-03-18 Eli Lilly And Company Aryloxyphenylpropylamines for obtaining a psychotropic effect
US4314081A (en) 1974-01-10 1982-02-02 Eli Lilly And Company Arloxyphenylpropylamines
GB1498857A (en) * 1975-07-03 1978-01-25 Leo Ab Antidepressant composition
JPS6056659A (ja) * 1983-09-08 1985-04-02 Yanmar Diesel Engine Co Ltd 農用トラクタ−のブレ−キ装置
CH658188A5 (de) * 1984-03-23 1986-10-31 Ciba Geigy Ag Lagerstabile schnellzerfallende pharmazeutische presslinge.
US4844908A (en) * 1986-11-27 1989-07-04 Duphar International Research B.V. Method of preparing tablets with clovoxamine fumarate and tablets thus prepared
GB8628359D0 (en) * 1986-11-27 1986-12-31 Zyma Sa Galenical formulation
GB8824392D0 (en) * 1988-10-18 1988-11-23 Ciba Geigy Ag Dispersible formulation
GB8921069D0 (en) * 1989-09-18 1989-11-01 Wellcome Found Pharmaceutically active compound,preparation and use
CA2039102A1 (en) * 1990-03-29 1991-09-30 David W. Robertson Compounds affecting serotonin receptors
CA2039103A1 (en) * 1990-03-29 1991-09-30 David Wayne Robertson Improvements in and relating to the selective occupation of serotonin 1c receptors
US5464632C1 (en) * 1991-07-22 2001-02-20 Prographarm Lab Rapidly disintegratable multiparticular tablet
DK0612242T3 (da) * 1991-11-15 2003-10-20 Sepracor Inc Anvendelse af ren S(+)-isomer af fluoxetin til fremstilling af et medikament mod migræne
JPH0656659A (ja) * 1992-06-10 1994-03-01 Natl Sci Council 直接打錠できる薬学組成物及びその錠剤の製造法

Also Published As

Publication number Publication date
RU2145850C1 (ru) 2000-02-27
TW404840B (en) 2000-09-11
ES2082723B1 (es) 1996-10-01
HU9502154D0 (en) 1995-09-28
NO952863L (no) 1996-01-22
PL309721A1 (en) 1996-01-22
EP0693281A2 (de) 1996-01-24
NO312225B2 (no) 2002-04-15
ES2082723A1 (es) 1996-03-16
PL181359B1 (pl) 2001-07-31
HUT75036A (en) 1997-03-28
ES2091737T3 (es) 2001-06-01
IL114641A0 (en) 1995-11-27
NO312225B1 (no) 2002-04-15
DK0693281T3 (da) 2001-05-21
FI20011852A7 (fi) 2001-09-20
FI953515L (fi) 1996-01-21
EP1072262A1 (de) 2001-01-31
AU692550B2 (en) 1998-06-11
CY2241B1 (en) 2003-07-04
CN1440745A (zh) 2003-09-10
GR3035788T3 (en) 2001-07-31
JPH0840884A (ja) 1996-02-13
HK1012573A1 (en) 1999-08-06
CO4410195A1 (es) 1997-01-09
KR100360130B1 (ko) 2003-01-29
FI20011851A7 (fi) 2001-09-20
FI20011852L (fi) 2001-09-20
FI121262B (fi) 2010-09-15
AU8317498A (en) 1998-11-05
FI20011851L (fi) 2001-09-20
GR960300064T1 (en) 1996-11-30
SI0693281T1 (en) 2001-12-31
DE69520768T2 (de) 2001-08-23
EP0693281A3 (de) 1996-10-30
FI953515A0 (fi) 1995-07-20
US5747068A (en) 1998-05-05
BR9503386A (pt) 1996-02-27
CZ188095A3 (en) 1996-02-14
PT693281E (pt) 2001-08-30
NZ272610A (en) 1997-08-22
CN1440745B (zh) 2012-03-21
DE69520768D1 (de) 2001-05-31
KR960003720A (ko) 1996-02-23
CN1123142A (zh) 1996-05-29
ES2091737T1 (es) 1996-11-16
TR199500878A2 (tr) 1996-06-21
EP1070501A1 (de) 2001-01-24
CN1101187C (zh) 2003-02-12
NO952863D0 (no) 1995-07-19
UA41346C2 (uk) 2001-09-17
EP0693281B1 (de) 2001-04-25
MY114776A (en) 2003-01-31
AU707210B2 (en) 1999-07-08
ZA956074B (en) 1996-05-14
AU2509895A (en) 1996-02-01
DE693281T1 (de) 1997-04-03
CZ287378B6 (en) 2000-11-15
IL114641A (en) 1999-04-11
PE33996A1 (es) 1996-09-09
HU228859B1 (en) 2013-06-28

Similar Documents

Publication Publication Date Title
ATE200733T1 (de) Pharmazeutische zubereitungen, die fluoxetin enthalten
HUP0004383A2 (hu) Hatóanyagként klodronátot és vivőanyagként szilíciumozott mikrokristályos cellulózt tartalmazó gyógyszerészeti készítmény
AU2002225772A1 (en) Therapeutic agents and methods of use thereof for treating an amyloidogenic disease
DE60120648D1 (de) Formulierungen von copolymer 1 (glatirameracetat) zur oralen, nasalen und pulmonalen verabreichung
AU2002231889A1 (en) Halogenated composition, method for preparing same and uses thereof
BR9504573A (pt) Formulaçao farmaceutica adequada para fabricaçao de tabletes dispersiveis por compressao direta tablete de cefaclor dispersivel e processo para fabricaçao de um tablete dispersivel contendo cefaclor
HUP9902415A2 (hu) Azonnal felszabaduló szilárd beadási formák és eljárás azok előállítására
CA2340734A1 (en) Optically active pyridyl-4h-1,2,4-oxadiazine derivative and its use in the treatment of vascular diseases
EP0744176A3 (de) Arzneimittel zur Hemmung von Knochenschwund
NZ516765A (en) Topical formulations comprising skin penetration agents and the use thereof
WO2002062952A3 (en) Non-cytotoxic pap mutants
MXPA02011533A (es) Nuevas formulaciones de alfa-2,4-disulfofenil-n-terc-butilnitrona.
CA2091134A1 (en) Therapeutic agent for threatened abortion
GEP20043377B (en) Pharmaceutical Complex
DE50202865D1 (de) Herstellung reiner stereoisomere von tricyclo-[5.2.1.0(2.6) ]-dec-9-yl-xanthogenat sowie deren verwendung als arzneimittel
NO308195B1 (no) Anvendelse av benzydamin til fremstilling av et legemiddel ved behandling av patologiske tilstander forÕrsaket av TNF
MY131159A (en) New pharmaceutical compositions containing epinastine and pseudoephedrine
SE0002354D0 (sv) New formulation
UA41326C2 (uk) Фармацевтична композиція для профілактики або лікування вірусних захворювань, засіб для профілактики або лікування вірусних захворювань
HRP20040165B1 (hr) Upotreba citaloprama u liječenju povišenog krvnogtlaka

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification